3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Head & Neck
3
Thoracic
2
Genitourinary
2
Breast
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Ovarian Neoplasms
57
Carcinoma, Ovarian Epithelial
28
Fallopian Tube Neoplasms
20
Uterine Cervical Neoplasms
17
Endometrial Neoplasms
17
Breast Neoplasms
13
Stomach Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
9
Prostatic Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Esophageal Neoplasms
7
Carcinoma, Renal Cell
7
Peritoneal Neoplasms
6
Melanoma
6
Uterine Neoplasms
4
Urinary Bladder Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma
4
Pancreatic Neoplasms
4
Neoplasms
4
Head and Neck Neoplasms
4
Esthesioneuroblastoma, Olfactory
4
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Triple Negative Breast Neoplasms
3
Salivary Gland Neoplasms
3
Kidney Neoplasms
3
Brenner Tumor
3
Interventions
pembrolizumab
3
Trastuzumab
3
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Interleukin-12 Subunit p35
2
Cisplatin
2
Carboplatin
2
trastuzumab deruxtecan
1
tivozanib
1
tipifarnib
1
seribantumab
1
pertuzumab
1
motexafin lutetium
1
lenvatinib
1
entinostat
1
atezolizumab
1
Specimen Handling
1
Peripheral Blood Stem Cell Transplantation
1
Ondansetron
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Interleukin-12
1
Injections
1
Immunohistochemistry
1
Ifosfamide
1
Hyperthermic Intraperitoneal Chemotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Docetaxel
×
Gynecologic
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled